CURE Pharmaceutical Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, revenue was USD 2.2 million compared to USD 3.33 million a year ago. Net loss was USD 14.77 million compared to USD 4.49 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to USD 0.09 a year ago.